Breaking News Instant updates and real-time market news.

SGMO

Sangamo

$8.71

-0.09 (-1.02%)

07:37
02/20/19
02/20
07:37
02/20/19
07:37

Sangamo: FDA accepts IND application for ST-920

Sangamo Therapeutics announced that the U.S. FDA has accepted the Investigational New Drug application for ST-920, a gene therapy candidate being evaluated for the treatment of adults with Fabry disease. Current standard of care for this rare, progressive condition involves regular lifelong infusions of enzyme replacement therapy. The active IND enables Sangamo to initiate a Phase 1/2 clinical trial designed to assess the safety, tolerability and efficacy of ST-920 in adults with Fabry disease. Sangamo expects to open several clinical sites later this year.

SGMO Sangamo
$8.71

-0.09 (-1.02%)

02/07/19
PIPR
02/07/19
NO CHANGE
Target $75
PIPR
Overweight
Crispr Therapeutics sell-off 'unfounded,' Overweight reiterated at Piper Jaffray
Piper Jaffray analyst Edward Tenthoff reiterated an Overweight rating and $75 price target on Crispr Therapeutics (CRSP). In a research note to investors, Tenhoff noted that Crispr and the broader gene editing space are selling off in reaction to Sangamo's (SGMO) presentation of interim data from the first in vivo gene editing study at WORLD Symposium 2019, which showed no meaningful changes in IDS or GAG levels in six patients after 23 weeks. Tenthoff says he does not see read-through to Crispr and that he believes CTX001 ex vivo approach and biological rational of targeting fetal hemoglobin de-risk and differentiate Crispr and that he is a buyer on "unfounded" sell-off in shares.
02/07/19
WELS
02/07/19
NO CHANGE
Target $24
WELS
Outperform
Wells Fargo says buy Sangamo on today's 'overdone' selloff
Wells Fargo analyst Jim Birchenough lowered his price target for Sangamo Therapeutics to $24 from $39 following today's update for in-vivo gene editing in mucopolysaccharidosis type I and II. While overall results are disappointing in terms of markers of sustainable efficacy and suggest further optimization required of gene editing efficiency and delivery, individual patient validation with significant iduronate-2-sulfatase enzyme production in one of two high dose MPSII patients and evidence of enzyme production in MPSI is encouraging, Birchenough tells investors in an intraday research note titled "Over Reaction To In-Vivo Gene Editing Update." The analyst believes Sangamo shares are "oversold" on today's news and recommends buying on the weakness. He maintains an Outperform rating on the name. Sangamo shares in in afternoon trading are down 36%, or $4.28, to $7.74.
02/08/19
JEFF
02/08/19
NO CHANGE
Target $23
JEFF
Buy
Jefferies sees opportunity in Sangamo after selloff, drops target to $23
Jefferies analyst Maury Raycroft says his Buy thesis on Sangamo Therapeutics is unchanged following yesterday's update. The analyst lowered his price target for the shares to $23 from $26 and maintains a Buy rating. Sangamo demonstrated successful in vivo editing, Raycroft tells investors in a research note. The analyst has confidence in the company's update, noting Sangamo was able to detect an albumin-IDS mRNA transcript in a liver biopsy aspirate that extracted around 100,000-300,000 cells for analysis. Further, concern about patient six and the transaminitis is likely an overreaction as liver enzyme elevation is consistent across gene therapy programs, adds the analyst. Raycroft sees opportunity in Sangamo shares following yesterday's selloff.
02/08/19
GSCO
02/08/19
NO CHANGE
Target $21
GSCO
Buy
Goldman says Orchard track record stands out amid disappointments in gene space
Goldman Sachs analyst Graig Suvannavejh noted that February 7 was "a day of disappointment" in the gene therapy and gene editing space, as Solid Biosciences (SLDB) and Sangamo (SGMO) both reported clinical efficacy data that missed investor expectations and "perhaps also raised concerns about the long-term promise of gene-based approaches." Within this context, he pointed out that he believes Orchard Therapeutics (ORTX) has "the most robust clinical experience in gene therapy, with over 150 patients treated across multiple product candidates and indications." The analyst, who expects new clinical data for Orchard candidates OTL-101 and OTL-102 to be presented later this month to re-affirm his confidence, reiterated his Buy rating and $21 price target on Orchard shares.

TODAY'S FREE FLY STORIES

EW

Edwards Lifesciences

$219.56

4.45 (2.07%)

04:58
09/23/19
09/23
04:58
09/23/19
04:58
Initiation
Edwards Lifesciences initiated  »

Edwards Lifesciences…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

ITW

Illinois Tool Works

$155.05

-0.91 (-0.58%)

, HON

Honeywell

$168.42

1.7 (1.02%)

04:55
09/23/19
09/23
04:55
09/23/19
04:55
Downgrade
Illinois Tool Works, Honeywell rating change  »

Illinois Tool Works…

ITW

Illinois Tool Works

$155.05

-0.91 (-0.58%)

HON

Honeywell

$168.42

1.7 (1.02%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 17

    Oct

04:55
09/23/19
09/23
04:55
09/23/19
04:55
General news
Breaking General news story  »

6-Month Bill Auction to…

HR

Healthcare Realty Trust

$33.17

-0.155 (-0.47%)

04:55
09/23/19
09/23
04:55
09/23/19
04:55
Conference/Events
Healthcare Realty Trust management to meet with Capital One »

Meetings to be held in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 23

    Sep

  • 24

    Sep

NBIX

Neurocrine

$100.74

-0.77 (-0.76%)

04:55
09/23/19
09/23
04:55
09/23/19
04:55
Conference/Events
Neurocrine participates in a conference call with JPMorgan »

SMid Biotechnology…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 23

    Sep

SIBN

SI-Bone

$20.18

0.28 (1.41%)

04:55
09/23/19
09/23
04:55
09/23/19
04:55
Conference/Events
SI-Bone management to meet with JMP Securities »

Meetings to be held in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 23

    Sep

  • 24

    Sep

  • 25

    Sep

TXN

Texas Instruments

$126.70

-2.1 (-1.63%)

04:55
09/23/19
09/23
04:55
09/23/19
04:55
Conference/Events
Texas Instruments management to meet with UBS »

Meeting to be held in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 23

    Sep

04:55
09/23/19
09/23
04:55
09/23/19
04:55
General news
PMI Composite FLASH â€' Level to be reported at 09:45 »

September PMI Composite…

CLDR

Cloudera

$9.00

0.33 (3.81%)

04:55
09/23/19
09/23
04:55
09/23/19
04:55
Conference/Events
Cloudera management to meet with Needham »

Meeting to be held in New…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 23

    Sep

  • 25

    Sep

IMAX

Imax

$21.83

0.04 (0.18%)

04:55
09/23/19
09/23
04:55
09/23/19
04:55
Recommendations
Imax analyst commentary  »

Imax management to meet…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 24

    Sep

KNSL

Kinsale Capital Group

$99.46

-1.68 (-1.66%)

04:55
09/23/19
09/23
04:55
09/23/19
04:55
Conference/Events
Kinsale Capital Group management to meet with RBC Capital »

Meetings to be held in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 23

    Sep

  • 24

    Sep

  • 25

    Sep

04:55
09/23/19
09/23
04:55
09/23/19
04:55
General news
PMI Composite FLASH Manufacturing â€' Level to be reported at 09:45 »

September PMI Composite…

HKMPY

Hikma

$0.00

(0.00%)

04:55
09/23/19
09/23
04:55
09/23/19
04:55
Conference/Events
Hikma participates in a conference call with JPMorgan »

European Pharma Equity…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 23

    Sep

  • 23

    Sep

  • 25

    Sep

DNOW

NOW Inc.

$12.05

-0.055 (-0.45%)

04:55
09/23/19
09/23
04:55
09/23/19
04:55
Conference/Events
NOW Inc. management to meet with KeyBanc »

Meeting to be held in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 23

    Sep

  • 06

    Nov

  • 11

    Nov

  • 12

    Nov

  • 13

    Nov

04:55
09/23/19
09/23
04:55
09/23/19
04:55
General news
Breaking General news story  »

3-Month Bill Auction to…

PRGO

Perrigo

$55.29

0.995 (1.83%)

04:55
09/23/19
09/23
04:55
09/23/19
04:55
Conference/Events
Perrigo management to meet with SunTrust »

Meetings to be held in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 23

    Sep

  • 24

    Sep

  • 01

    Oct

BRKR

Bruker

$43.62

0.06 (0.14%)

04:55
09/23/19
09/23
04:55
09/23/19
04:55
Conference/Events
Bruker management to meet with Needham »

Meetings to be held in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 23

    Sep

  • 24

    Sep

BABA

Alibaba

$182.43

1.96 (1.09%)

04:55
09/23/19
09/23
04:55
09/23/19
04:55
Conference/Events
Alibaba management to meet with KeyBanc »

Meetings to be held in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 23

    Sep

  • 24

    Sep

ETSY

Etsy

$60.39

1.34 (2.27%)

04:55
09/23/19
09/23
04:55
09/23/19
04:55
Conference/Events
Etsy management to meet with Oppenheimer »

Meetings to be held in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 23

    Sep

  • 24

    Sep

SPOT

Spotify

$120.73

-3.685 (-2.96%)

04:55
09/23/19
09/23
04:55
09/23/19
04:55
Conference/Events
Spotify management to meet with Morgan Stanley »

Group Breakfast Meeting…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 23

    Sep

WTTR

Select Energy Services

$9.02

0.11 (1.23%)

04:55
09/23/19
09/23
04:55
09/23/19
04:55
Conference/Events
Select Energy Services management to meet with Seaport Global »

Meeting to be held in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 23

    Sep

04:55
09/23/19
09/23
04:55
09/23/19
04:55
General news
Chicago Fed National Activity Index Level to be reported at 08:30 »

August Chicago Fed…

UPS

UPS

$120.71

1.61 (1.35%)

04:55
09/23/19
09/23
04:55
09/23/19
04:55
Conference/Events
UPS management to meet with UBS »

Meetings to be held in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 23

    Sep

MTDR

Matador

$17.04

0.25 (1.49%)

04:55
09/23/19
09/23
04:55
09/23/19
04:55
Conference/Events
Matador management to meet with RBC Capital »

Meetings to be held in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 23

    Sep

  • 24

    Sep

  • 25

    Sep

BPOP

Popular

$54.57

0.02 (0.04%)

04:55
09/23/19
09/23
04:55
09/23/19
04:55
Conference/Events
Popular management to meet with RBC Capital »

Meeting to be held in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 23

    Sep

  • 13

    Nov

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.